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doi:10.1Objective: Mechanical and biological prostheses are used to replace damaged heart valves but are associated
with significant morbidities. Although there is increased interest in bioengineering cell-seeded heart valve scaf-
folds, it is a time-consuming and technically difficult process. The goal of this project was to engineer self-
seeding heart valves that mature quickly in vivo and have a shorter preparation time.
Methods: Porcine pulmonary valves were decellularized using detergent methods and then either (1) left
untreated (unconjugated, n ¼ 6), (2) reseeded with autologous endothelial progenitor cell–derived endothe-
lial cells (cell-seeded, n ¼ 4), or (3) conjugated with CD133 antibodies (conjugated, n ¼ 8). The valve con-
structs were transplanted into the pulmonary position of sheep using standard surgical techniques. After 1 or
3 months, the implants were removed and assessed for cell and matrix content as well as biomechanical
properties.
Results: Endothelial cells expressing von Willebrand factor lined the entire length of both ventricular and ar-
terial surfaces of conjugated valves by 1 month after implantation. Interstitial cell and structural protein content
of conjugated valves increased from 1 month to 3 months with interstitial expression of metalloproteinase-9 and
new collagen formation. In contrast, there were few endothelial or interstitial cells associated with unconjugated,
or cell-seeded valves at any time point. No calcification or thrombi were noted on any of the valves. Young’s
modulus and tensile strength was greater in the conjugated valves versus unconjugated or cell-seeded valves.
Conclusions: Results indicate that tissue-engineered heart valve replacement constructs can be made quickly
and therefore may be a clinically relevant option for patients needing heart valve surgery in a timely fashion.
(J Thorac Cardiovasc Surg 2012;143:201-8)Valvular heart disease is a common diagnosis worldwide,
with many of these patients eventually needing an oper-
ative intervention. From 1998 to 2005, approximately
300,000 valve replacement operations were performed
in the United States alone.1 Whereas valve replacement
surgery has evolved since the early 1950s, when it was
first described as an experimental procedure in dogs,2
major clinical advances in valve replacement constructs
have lagged. There still exist only 2 basic alternatives,
mechanical and biological prostheses, both of which
have significant limitations. Serious complications aris-
ing from all types of valve replacements run about 2%
to 4% and include thromboembolism, size mismatch, en-
docarditis, mechanical dysfunction, and hemolysis.3 Me-
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Syears but are associated with life-long anticoagulation
treatment and the concomitant risk of thromboembolism
and bleeding.4 Bioprostheses generally have better hemo-
dynamic characteristics and avoid long-term anticoagula-
tion therapies but are associated with progressive tissue
deterioration.5 Furthermore, all commercially available
tissue valve substitutes are nonviable with minimal po-
tential to grow, repair, or remodel. Therefore, their clin-
ical utility is limited, especially in growing children.6,7
These limitations tend to guide surgeons in choosing
a replacement construct to match the patient’s age and
lifestyle. Living tissue replacements with the capacity
for growth and regeneration provide fundamental
advantages over the currently available cardiovascular
replacements.
Tissue-engineering techniques may play a prominent fu-
ture role in the development of heart valve replacement
therapy. The principal goal of tissue-engineered heart valve
(TEHV) construction is to create living tissue that, in re-
sponse to repeated applications of complex shear forces
and bending stress, heals and regenerates instead of becom-
ing calcified or developing other structural abnormalities.
The ideal prosthetic valve would have the following charac-
teristics: (1) widely available ‘‘off the shelf’’; (2) normal
hemodynamic performance; (3) low risk for thromboembo-
lism, endocarditis, calcification, and/or degeneration; and
(4) ability to grow and self-repair. Tissue-engineeringrdiovascular Surgery c Volume 143, Number 1 201
Abbreviations and Acronyms
ECM ¼ extracellular matrix
EPC ¼ endothelial progenitor cell
MMP-9 ¼ matrix metalloproteinase-9
GAG ¼ glycosaminoglycans
TEHV ¼ tissue-engineered heart valve
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Stechniques provide an opportunity to provide significant im-
provements in valve replacement technology.
An early TEHV was the Synergraft decellularized homo-
graft prosthesis (CryoLife Inc, Kennesaw, Ga). It was
thought that host cells would repopulate the decellularized
scaffold and provide the functions of a living valve: grow-
ing, healing, resistance to infection, and creation of an ex-
tracellular matrix (ECM). Although histologic studies
demonstrated recipient cells within these grafts,8 the func-
tionality of these cells is unclear as evidenced by some early
degeneration.9 These findings suggest that providing only
a scaffold for passive in vivo seeding will likely not suffice
in the long-term.
More recent laboratory efforts have focused on identify-
ing appropriate scaffold materials, progenitor cell sources,
and seeding/conditioning techniques. TEHV grown from
autologous cells seeded on biodegradable synthetic poly-
mers and matured in vitro have functioned in the pulmonary
circulation of growing lambs for up to 5 months.10 How-
ever, this involves the time-consuming task of isolating
and culturing cells before adding them to a valve construct
and then conditioning the resulting construct in vitro, a pro-
cess that can take manyweeks or evenmonths. In this proof-
of-concept study, we hypothesize that in vitro conjugation
of decellularized pulmonary valve constructs with CD133
antibodies promotes rapid in situ self-seeding, remodeling,
and maturation of normal heart valve structure and cell
function.MATERIALS AND METHODS
Animal Studies
Studies were performed in accordance with the ‘‘Guide for the Care and
Use of Laboratory Animals’’ (1996) published by the National Institutes of
Health under a protocol approved by the Wake Forest School of Medicine
Animal Care and Use Committee.
Experimental Design
Female sheep (35-65 kg) were randomized to receive 1 of 3 types of
valve constructs, all of which were based on a decellularized porcine pul-
monary valve. The 3 groups were as follows: (1) unconjugated (n¼ 6); (2)
cell-seeded (n¼ 4); and (3) conjugated (n¼ 8). Unconjugated valves were
decellularized porcine valves with no additional treatment. Cell-seeded
valves were decellularized valves that were seeded with autologous endo-
thelial cells 1 week before implantation. Conjugated valves were decellu-
larized valves that underwent a protocol to attach an antibody that
recognized sheep CD133, an endothelial progenitor cell (EPC) marker.202 The Journal of Thoracic and Cardiovascular SurgDecellularization Protocol
Decellularized constructs were prepared from porcine pulmonary
valves isolated as previously described.11 The pulmonary valve was dis-
sected from the heart, leaving 2-cm margins on each side of the annulus.
The constructs were then decellularized using water lysis and treatment
with Triton X-100 (Dow Chemical Company, Midland, Mich) and ammo-
nium hydroxide. The constructs werewashed thoroughly before glutaralde-
hyde fixation and sterilization by gamma irradiation.
Cell Collection
EPCs were isolated from sheep using a technique similar to that previ-
ously described.12 In brief, an arteriovenous shunt was established using
the femoral vessels into which a sterile stem cell purification cartridge
(CD133 antibody bound to sepharose beads) was placed. After the column
was removed from the circulation, the beads were removed from each col-
umn and rinsed over mesh filters to remove unbound cells. Cells were
passed through a new mesh strainer to remove the beads, pelleted by cen-
trifugation, and resuspended in endothelial cell growth media 2 (EGM-2;
Cambrex, East Rutherford, NJ).
Cell Culture/Seeding and Construct Conditioning
Cells were cultured with endothelial cell growth media 2 for 24 hours
before the unattached cells were transferred to fibronectin-coated culture
plates and differentiated until cells with endothelial morphologic character-
istics were visible and proliferating. Cultures were split at 70% confluence
until 2 3 106 cells were obtained, usually by the fourth passage. Endothe-
lial cells (1.5 3 106 cells/mL in Dulbecco modified Eagle medium) were
seeded onto the valve matrix systematically to distribute them as evenly
as possible. Cells were seeded on a small area (ie, ventricular surface of
a leaflet) and allowed to attach before rotating the valve construct and seed-
ing the next area. This process continued until the entire surface had been
covered.
After the seeding process, the constructs were cultured for 7 days before
being conditioned in a computer-assisted, flow-dependent bioreactor
system, as previously described.11 Flow and pressurewere monitored to en-
sure that physiologic conditions were maintained throughout conditioning.
After the scaffolds had been seeded, cell-seeded valves were conditioned in
a low-flow (500 mL/min), low-pressure (25/10 mm Hg at 100 beats/min)
environment for 7 days before being removed, washed, and implanted
into sheep. The seeding and conditioning protocols were tested and their
success verified by histology and immunohistochemistry at each of these
steps before the in vivo studies.
Valve Conjugation
An antihuman CD133 monoclonal antibody was prepared from the
AC133.1 hybridoma line (ATCC, Manassas, Va) using a hollow-fiber
unit with serum-free medium (SFM4MAB; Hyclone, Logan, Utah) as pre-
viously described.12 The antibody was purified with protein G cartridges
and concentrated into a neutral pH saline. Conjugation of the gas-
sterilized decellularized heart valve occured in 2 steps within 24 hours of
implantation. First, the scaffold was activated with N-ethyl-N0-3-(dimethy-
laminopropyl)carbodiimide (0.19 g/100 mL buffer); then the antibody
(5 mg/mL) was added at a ratio of 500 mg/mL in N-hydroxy succinimide.
Valve Replacement Procedure
Sheep (35-65 kg) were premedicated with ketamine and glycopyrrolate,
intubated, and anesthetized with isofluorane before placement of a central
venous catheter. With mechanical ventilation, a left thoracotomy was per-
formed, and after anticoagulation, normothermic right atrial–carotid artery
cardiopulmonary bypass was established with a single-stage venous cathe-
ter, a peripheral arterial perfusion cannula (12F-16F), and a Capiox FX15
oxygenator (Terumo Cardiovascular Systems, Ann Arbor, Mich) with ve-
nous blood directly returned to the reservoir. The pulmonary artery wasery c January 2012
Jordan et al Evolving Technology/Basic Sciencetransversely incised and the native pulmonary valve leaflets were excised.
The experimental valve conduit was sutured in place with continuous 5-0
polypropylene sutures and the animal weaned from the bypass circuit. Af-
ter anastomotic hemostasis had been assured, the cannulas were removed,
the incisions were closed, and the animal was allowed to recover. Antibi-
otics and analgesia were given systematically and the animals were main-
tained postoperatively for either 1 or 3 months.
Tissue Harvest
At the appropriate time postoperatively, the sheep were again prepared
for surgery (as described earlier). The heart was dissected free from the
chest wall and lungs, excised, and rinsed with saline. The construct was dis-
sected free from the heart, and samples from the leaflets and pulmonary ar-
tery wall were taken for histologic, biochemical, and biomechanical
testing. One leaflet each was used for biomechanical testing, biochemical
analysis, and histologic sectioning.
Histology
Frozen sections were prepared using paraformaldehyde/glucose/
optimal cutting temperature embedding media and standard histologic
techniques. Sections were stained with either hematoxylin and eosin (for
general architecture) or Herovici stain for collagen formation. In addition,
a series of immunohistochemical staining methods was employed using
specific primary antibodies and methods well established in our laborato-
ries.12 Immunostaining for CD31, von Willebrand factor (endothelial
cells), and alpha-smooth muscle actin (interstitial cells) was used to eval-
uate expression patterns within the valve leaflets. Sections were also
stained for matrix metalloproteinase-9 (MMP-9). Monoclonal antibodies
(Santa Cruz, Santa Cruz, Calif) were used in all cases with appropriate se-
rum controls and native sheep leaflets for positive controls.
ECM Content
Biochemical evaluation of the ECM was performed on 1 leaflet using
established methods.13 In brief, sulfated glycosaminoglycans (GAGs)
and collagen were determined using the Blyscan sulfated GAG assay kit
(Biocolor Ltd, Carrickfergus, United Kingdom) and Sircol collagen assay
kit (Biocolor), respectively. These kits used quantitative dye-binding
methods to determine the total quantity of the respective ECM component
in the sample.
Biomechanical Testing
One leaflet from each sheep was tested for biomechanical characteris-
tics using a uniaxial load test machine. Tensile strength testing was done
at room temperature with a 100-N load cell. Leaflet samples (3 mm width,
full length) were prepared, attached at both ends to an atraumatic clamp,
and subjected to uniaxial tensile loading to failure. Stress–strain relation-
ships were compared between all groups to ensure maintenance of struc-
tural integrity.
SRESULTS
Surgical Implantation
Eighteen animals were entered into the study with 16
completing the specified duration of implantation. One ani-
mal could not be weaned from bypass and never left the op-
erating room. The second (conjugated group) died in the first
postoperative week of non–cardiac related complications.E
T
/BCell-Seeded Constructs
EPCs were isolated from the circulation using the affinity
column and grew to 2 3 106 cells within 12 days,The Journal of Thoracic and Caexpressing endothelial cell markers as previously re-
ported.12 The porcine valves were successfully decellular-
ized and contained no DNA material while maintaining
their collagen and elastin architecture as previously de-
scribed.11 After seeding and conditioning in the bioreactor,
endothelial cells could be seen forming a confluent mono-
layer over 80% to 90% of the valve leaflets as previously
reported.12
CD133 Conjugated Constructs
Conjugation took approximately 2 hours and the valves
were implanted within 24 hours following the conjugation
procedure. Five decellularized valves were conjugated
with fluorescein isothiocyanate–labeled CD133 and placed
in phosphate-buffered saline solution (with daily buffer
changes) for 5 days. Daily, 1 valve was removed and exam-
ined for the presence of green fluorescence, indicating the
continued presence of the coupled antibody. When present
(out to day 4), fluorescence was concentrated on both leaflet
surfaces but was also detected throughout its entire thick-
ness (Figure 1). Three additional valves were conjugated
with CD133–fluorescein isothiocyanate, placed in the bio-
reactor, and conditioned as described earlier. Valves were
removed 1, 3, and 5 days after conditioning. All fluores-
cence was gone after 3 days (Figure 1).
Valvular Cell Content
Hematoxylin and eosin staining was used to assess cell
content in the leaflets after 1 and 3 months in situ. After 1
month in vivo, cells were virtually nonexistent on unconju-
gated valve leaflets. Despite seeding with EPC-derived en-
dothelial cells before implantation, cell-seeded valves did
not display substantially more cells than the unconjugated
controls. However, there was clear nuclear staining along
the ventricular edge of the leaflet that extended through
the lamina radialis into both the lamina spongiosa and fi-
brosa of conjugated valves. At 3 months, the results were
nearly identical in both unconjugated and cell-seeded
groups (Figure 2, A), whereas even more nuclei were dis-
tributed throughout the lamina spongiosa and fibrosa of
conjugated valves. In addition to more nuclei, hematoxylin
and eosin staining revealed an increase in eosinophilic
staining throughout the spongiosa and fibrosa regions,
likely owing to increased collagen.
To determine the distribution and density of cells in the
conjugated valves, we used 4,6-diamino-2-phenylindole
staining (Figure 2, B). Beginning as early as 1 week (deter-
mined in 1 animal that died of noncardiac complications),
high densities of cells were observed along the edges of
the leaflets. By 1 month, this had reached confluence along
the ventricular side of the leaflet with increasing cell content
across all lamina, but especially within the lamina fibrosa.
At 3 months, all layers of the conjugated leaflets were
cell-rich and densely populated.rdiovascular Surgery c Volume 143, Number 1 203
FIGURE 1. Time course of antibody washout. Fluorescein isothiocyanate–labeled CD133 antibodies were conjugated to decellularized pulmonary valve
constructs before being washed statically (not shown) or in a bioreactor for 3 days. Immediately after conjugation, intense fluorescence identified densely
conjugated antibodies throughout the leaflet surface and lamina. After 3 days in the bioreactor, fluorescent intensity was reduced but not completely absent,
suggesting that some antibody remains available to attract cells for at least 3 days after implantation.
FIGURE 2. A, Cell content after 3 months in vivo. Hematoxylin and eosin staining of valve leaflets. Conjugated valves exhibited nuclear staining across the
entire valve with a predominance of cells along the leaflet edge. Unconjugated and cell-seeded valves had no or few cells, which were limited to the edges.
B, 4,6-Diamino-2-phenylindole staining of nuclei of conjugated valve leaflets after 1 week, 1 month, and 3 months in vivo. Conjugated leaflets exhibited
a progressive recellularization across the entire leaflet.
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FIGURE 3. Cell types in conjugated leaflets after 3 months in vivo. Conjugated leaflets show specific staining for the endothelial cell marker, von Wil-
lebrand factor (vWF), predominantly along the surface of the leaflet where endothelial cells would congregate. Similarly, though more widespread, conju-
gated leaflets exhibit specific staining for the interstitial cell marker alpha-smooth muscle actin (a-SMA).
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mine the types of cells distributed throughout the conju-
gated valve leaflets. Figure 3 illustrates a predominance of
von Willebrand factor–positive cells along the edge of the
leaflets where endothelial cells are expected to reside. Fur-
thermore, antibodies directed against smooth muscle actin
show a broader distribution with intense staining through-
out the lamina of the leaflet, suggesting that these are valvu-
lar interstitial cells.
Together, these data suggest that conjugated valves
quickly and efficiently ‘‘self-seed’’ when implanted into
the body, whereas the unconjugated valves show little recel-
lularization. Not only are these valves densely populated
with cells, but multiple cell types have become differen-
tially distributed across the leaflets. Both endothelial cells
and interstitial cells have populated the leaflets of conju-
gated valves, appearing to have migrated to the appropriate
anatomic location. Despite placing cells onto the construct
before implantation, it appears that most of these cells were
lost from the scaffold within the first month in the cell-
seeded group. The fate of these cells was undetermined,
but their loss is likely the result of detachment from the
scaffold.
Valvular Maturation and Remodeling
Although cells of the correct phenotype are important,
these cells must be functional to mimic native valves.
New collagen formation was qualitatively assessed using
Herovici stain. Figure 4, A, compares new collagen (blue
staining) production in the 3 groups after 3 months
in vivo. All 3 groups show development of new collagen fi-
bers along the borders of the leaflets. However, there is littleThe Journal of Thoracic and Caor no new collagen formation within the lamina fibrosa or
spongiosa in either unconjugated or cell-seeded leaflets.
In contrast, there is a widespread distribution of new colla-
gen fibers in conjugated leaflets. This qualitative assessment
was confirmed by a biochemical determination of acid-
soluble collagen. Both unconjugated and cell-seeded valves
exhibited a slight decrease in collagen content over time
(Table 1), whereas conjugated valves significantly in-
creased the collagen content from 1 to 3 months.
Similar to collagen, there was a decrease in the amount of
sulfated GAGs over time in the unconjugated and cell-
seeded leaflets (Table 1). Again, conjugated valves ex-
hibited an increase in sulfated GAG content at 3 months
compared with the 1-month time point. Together, these
data demonstrate production of matrix proteins by the cells
attracted to the conjugated valve leaflets.
For remodeling to occur, not only do new matrix proteins
need to be made, but older structural components must be
removed. Figure 4, B, demonstrated the wide distribution
of MMP-9 activity (brown staining) in the conjugated leaf-
lets, suggesting that interstitial cells within the various lam-
ina of the leaflet are using MMP-9 to break down structural
proteins (collagen). In all, these data provide evidence that,
in conjugated valves, the cells that have located to the leaf-
lets are active participants in the maturation and remodeling
of these leaflets. Such activity is missing in the unconju-
gated and cell-seeded valve leaflets.
Biomechanical Properties
Measurements of elasticity and tensile strength were
assessed in the leaflets of all 3 groups. There were no dis-
cernible differences in either group or time related to therdiovascular Surgery c Volume 143, Number 1 205
FIGURE 4. Formation and degradation of extracellular matrix (ECM) components. A, Using Herovici stain on sections of leaflets after 3 months
in vivo, all groups exhibit signs of new collagen formation (blue staining). In unconjugated leaflets, this staining is limited solely to the leaflet
edge whereas it is more widespread in the other groups. Conjugated valves clearly have the largest amount of new collagen formation at this time
point. B, Remodeling requires both the production and degradation of the ECM. Here, matrix metalloproteinase-9 (MMP-9) activity is assessed using
immunohistochemical techniques. Conjugated valves show widespread MMP-9 activity throughout the inner lamina of the leaflet. This activity is ab-
sent in unconjugated leaflets.
TABLE 1. Biochemical analysis of ECM components and biomechanical properties
Experimental groups
Acid–soluble
collagen (mg/0 mg)
Sulfated GAGs
(mg/10 mg)
Young’s modulus
(MPa)
Tensile strength
at break (MPa)
Normal pig valves (n ¼ 5) 474  70 52  7 5.2  0.5 3.0  0.3
Unseeded, 1 mo (n ¼ 3) 374  70 52  7 2.2  0.5 1.0  0.3
Unseeded, 3 mo (n ¼ 3) 275  82 22  5 2.0  0.8 1.5  0.2
Cell seeded 1 mo (n ¼ 2) 415  42 44  10 3.0  2.0 1.0  1.0
Cell seeded, 3 mo (n ¼ 2) 370  50 35  7 3.0  1.0 1.5  1.0
Conjugated, 1 mo (n ¼ 4) 431  56 45  9 3.0  1.0 2.5  0.5
Conjugated, 3 mo (n ¼ 4) 587  72 64  9 6.0  2.0 3.1  1.0
GAG, Glycosaminoglycan.
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Stensile strength of the leaflets between unconjugated and
cell-seeded valves (Table 1). The tensile strength of conju-
gated valves was elevated 1 month after implantation and
continued to rise out to 3 months. However, this change in
elasticity does not represent a large biological change.
DISCUSSION
The main findings of the study were as follows: (1) col-
lecting, expanding, preseeding, and preconditioning valve
constructs was a lengthy and challenging process; (2) the
conjugation process was relatively quick and easy—conju-
gated CD133 remained on the scaffold for 3 days in a biore-
actor, which may mimic its life expectancy in vivo; (3)
conjugation produced a more cell-rich valve construct; (4)
while functional remodeling was not assessed in this exper-
iment, it appears that conjugated valves were producing the
ECM and remodeling proteinases; (5) the biomechanical
properties of conjugated valves were closer to those of nor-
mal valves than the other valve constructs.
Many efforts to create TEHVs have focused on scaffold
material, culturing cells, and then using appropriate seeding
and preconditioning protocols.14-18 Clinical use of these
constructs began with isolated cases reported in the past
decade19-21 using decellularized allografts seeded with
autologous cultured endothelial cells. Follow-up (1-6 years)
showed no mortality or significant morbidities, suggesting
that TEHVmay be a viable alternative to current valve tech-
nology. Others have reported on their early experience us-
ing autologous peripheral blood mononuclear cells in
conjunction with a decellularized allograft matrix in pediat-
ric patients.22 Peripheral blood mononuclear cells were dif-
ferentiated directly on the valve scaffold for up to 3 weeks in
a bioreactor before surgery. Follow-up occurred over 3.5
years with the TEHV showing excellent performance and
hemodynamics with no signs of valvular stenosis, degener-
ation, cusp thickening, or decreased mobility. The authors
even suggest that the valve grew with the patients. Larger
clinical trials evaluating TEHVs are in their early stages.
Dohmen and associates23 reported a series of 23 patients un-
dergoing the Ross procedure who received a TEHV. In this
study, decellularized grafts were seeded with autologous
endothelial cells and cultured in a bioreactor. Follow-up
showed no changes in mean flow velocities or regurgitation
in the TEHV. Together, these results suggest that TEHVs
may be feasible and safe with the potential to grow and re-
model with younger patients.
The development of long-lasting, functional, and self-
repairing TEHVs depends on the cells that populate the con-
struct and dictate the structural, functional, and remodeling
processes of the valve. To this end, the valvular endothelial
cells and valvular interstitial cells play a vital role in the
health, function, and repair of the valve apparatus. The first
hurdle to overcome is getting the proper cells to locate ap-
propriately within the structure of the valve leaflets, withThe Journal of Thoracic and Caendothelial cells lining the edges and interstitial cells dis-
tributed throughout the lamina. Here we have demonstrated
that conjugating an antibody against EPCs (CD133) to a de-
cellularized valve construct, host cells can quickly repopu-
late the construct. Within 1 month, substantial cell
accumulation had occurred along the edges of the leaflets,
and by 3 months, cell density had increased throughout
the leaflet. In our hands, this directed recellularization
was far more efficient and effective than implantation of ei-
ther decellularized valves (passive migration) or valves that
were reseeded with endothelial cells before implantation.
Although cell seeding did not prove effective in our hands,
others have had more success, albeit with methods that re-
quire substantial time and effort.19-23
The potential of TEHV to remodel and grow with a pa-
tient, especially important in younger patients, was not di-
rectly assessed in this study. Interstitial cells are located
throughout the valve leaflet and are tightly coupled to the
ECM by forming new matrix proteins (collagen) as well
as enzymes used to break down these structural compo-
nents.24 These interstitial cells are quite active during devel-
opment and may also be activated owing to injury or stress
in adult tissues. Furthermore, the interaction between valvu-
lar interstitial cells and the ECM may play a role in the de-
velopment of pathologic states such as calcification.25 Here
we show evidence of valvular interstitial cell–like activity
from cells positive for smooth muscle actin located through-
out the various lamina of the valve leaflet. Conjugated
valves had significantly elevated levels of collagen and
GAG production, 2 important components of the ECM of
valve leaflets. These data suggest an active participation
of interstitial cells to remodel the decellularized graft and
the potential for them to be involved in regulated construct
growth and self-repair mechanisms over time.
The primary goal of the project was to demonstrate effi-
cacy of in situ self-seeding valves and the ability of these
constructs to remodel. Here, we focused on the histologic
and cellular function of the cells populating the constructs.
Also, in light of the large differences in the qualitative mea-
sures of cellularization and remodeling observed, coupled
with the speed and ease of creating self-seeding TEHV, we
determined that pursuing preseeded valves was not justified.
Although there are limitations to this work, including length
of study, lack of functional evaluation, and small numbers of
animals studied, the data represent a proof-of-concept for
the self-seeding TEHV. Thus, although the early time points
examined are appropriate here, longer studieswill need to be
performed in the future. Similarly, valve function and dura-
bility will need to be examined as this work progresses.
CONCLUSIONS
On the basis of the data presented here, it may be unnec-
essary to culture, seed, and condition autologous cells on
a scaffold to create a viable TEHV. By providing a meansrdiovascular Surgery c Volume 143, Number 1 207
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the time-consuming and technically demanding process of
reseeding a valve construct may be bypassed. Conjugated
valves have several other distinct advantages over autolo-
gous pre–cell-seeded valves. First, these constructs may
be available quickly (within 24 hours), thus reducing the
time until surgery can be scheduled. Second, these valves
require no special handling techniques (either from the hos-
pital or from the surgeon), thus facilitating their usage.
Third, these valves may have the potential to grow with
the patient, reducing the number of possible reinterventions
experienced over a lifetime for those patients receiving
them during childhood or early adulthood.
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